Exchange
HKEX
Every company in the roster listed on HKEX.
Research
Compare financial metrics on this exchange
Research adds market cap, cash, runway and annualized R&D metrics with metric-specific sorting.
Views
44 of 44 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Hansoh Pharmaceutical Group3692 · HKEX | 15 assets: 8 Ph 3, 4 Ph 2, 3 Ph 1 | HS-20094Phase 3 · ObesityReliable signal | 30 Oct 2026HS-20118 · Phase 1 |
 Innovent Biologics1801 · HKEX | 13 assets: 9 Ph 3, 2 Ph 2, 2 Ph 1 | IBI305Phase 3 · Non-Small Cell Lung CancerReliable signal | 31 Oct 2026IBI3003 · Phase 1/2 |
 Shanghai Henlius Biotech2696 · HKEX | 13 assets: 7 Ph 3, 4 Ph 2, 2 Ph 1 | HLX01Phase 3 · Rheumatoid ArthritisReliable signal | 22 Oct 2026Serplulimab · Phase 2 |
 Sino Biopharmaceutical1177 · HKEX | 13 assets: 1 approved, 6 Ph 3, 3 Ph 2, 3 Ph 1 | CulmerciclibPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signal | Dec 2026Culmerciclib · Phase 3 |
 Akeso9926 · HKEX | 11 assets: 7 Ph 3, 4 Ph 2 | PenpulimabPhase 3 · Non-Small Cell Lung CancerReliable signal | 22 Oct 2026AK138D1 · Phase 1 |
 CSPC Pharmaceutical Group1093 · HKEX | 11 assets: 8 Ph 3, 2 Ph 2, 1 other | DBPR108Phase 3 · Type 2 DiabetesReliable signal | 10 Oct 2026Ammoxetine · Phase 1 |
 Luye Pharma Group2186 · HKEX | 9 assets: 2 approved, 3 Ph 3, 1 Ph 2, 3 Ph 1 | Ansofaxine hydrochloridePhase 3 · Major Depressive DisorderReliable signal | 28 Feb 2027Ansofaxine hydrochloride · Approved |
 Keymed Biosciences2162 · HKEX | 6 assets: 3 Ph 3, 2 Ph 2, 1 Ph 1 | stapokibartPhase 3 · Atopic DermatitisReliable signal | 2 Nov 2026CM512 · Phase 2 |
 Shanghai Junshi Bioscience1877 · HKEX | 6 assets: 1 approved, 1 Ph 3, 3 Ph 2, 1 Ph 1 | OngericimabPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | 27 Nov 2026JS207 · Phase 2 |
| 6 assets: 1 Ph 3, 4 Ph 2, 1 Ph 1 | KL-A167Phase 3 · Non-Small Cell Lung Cancer | 31 Dec 2026KL590586 · Phase 1/2 | |
 Alphamab Oncology9966 · HKEX | 4 assets: 4 Ph 3 | JSKN003Phase 3 · HR+/HER2- Metastatic Breast Cancer | 30 Dec 2026JSKN003 · Phase 3 |
 Ascletis Pharma1672 · HKEX | 4 assets: 3 Ph 3, 1 Ph 1 | DenifanstatPhase 3 · MASH / NASHReliable signal | Jul 2028ASC30 · Phase 3 |
 Beijing InnoCare Pharma Tech Co.9969 · HKEX | 4 assets: 3 Ph 3, 1 Ph 2 | ICP-488Phase 3 · PsoriasisPartial signal | 25 Nov 2026ICP-332 · Phase 3 |
 DualityBio Inc.9606 · HKEX | 4 assets: 2 Ph 3, 2 Ph 2 | BNT324Phase 3 · Non-Small Cell Lung Cancer | Aug 2027DB-1303 · Phase 1/2 |
 Jacobio Pharmaceuticals1167 · HKEX | 4 assets: 2 Ph 3, 2 Ph 2 | GlecirasibPhase 3 · Non-Small Cell Lung CancerWeak signal | 31 Dec 2026JAB-23E73 · Phase 1/2 |
 Simcere Pharmaceutical2096 · HKEX | 4 assets: 3 Ph 3, 1 Ph 1 | EndostarPhase 3 · Non-Small Cell Lung CancerPartial signal | 30 Sep 2027SIM0500 · Phase 1 |
 Xuanzhu Biopharmaceutical2575 · HKEX | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | XZP-3621Phase 3 · Non-Small Cell Lung CancerPartial signal | None on record |
 Abbisko Therapeutics2256 · HKEX | 3 assets: 2 Ph 2, 1 Ph 1 | ABSK043Phase 2 · Non-Small Cell Lung Cancer | Mar 2027ABSK112 · Phase 1 |
 Nanjing Leads Biolabs Co.,Ltd9887 · HKEX | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | LBL-024Phase 3 · Non-Small Cell Lung Cancer | 20 Oct 2026LBL-034 · Phase 1/2 |
 CARsgen Therapeutics Holdings Limited2171 · HKEX | 2 assets: 2 Ph 2 | Zevorcabtagene autoleucelPhase 1/2 · Multiple MyelomaWeak signal | 15 Jun 2027CT071 · Phase 1/2 |
 GenFleet Therapeutics2595 · HKEX | 2 assets: 1 Ph 3, 1 Ph 2 | GFH375Phase 3 · Non-Small Cell Lung Cancer | 30 Apr 2027GFH375 · Phase 2 |
 Hua Medicine2552 · HKEX | 2 assets: 1 Ph 3, 1 Ph 1 | DorzagliatinPhase 3 · Type 2 DiabetesPartial signal | None on record |
 ImmuneOnco Biopharmaceuticals1541 · HKEX | 2 assets: 2 Ph 2 | IMM2510Phase 2 · Non-Small Cell Lung Cancer | 20 May 2027ImmuneOnco anti-PAH candidate (IMC-003) · Phase 1 |
 Laekna Limited2105 · HKEX | 2 assets: 1 Ph 3, 1 Ph 1 | AfuresertibPhase 3 · HR+/HER2- Metastatic Breast Cancer | 30 Oct 2026Afuresertib · Phase 3 |
 Sunho Biologics2898 · HKEX | 2 assets: 1 Ph 2, 1 Ph 1 | IAP0971Phase 1/2 · Non-Small Cell Lung Cancer | 28 Feb 2027ISH0688 · Phase 1 |
 Suzhou Ribo Life Science6938 · HKEX | 2 assets: 1 Ph 2, 1 Ph 1 | RBD5044Phase 2 · Atherosclerotic Cardiovascular Disease | None on record |
 Vigonvita Life Sciences2630 · HKEX | 2 assets: 2 Ph 2 | LV232Phase 2 · Major Depressive DisorderWeak signal | 31 Oct 2027VV119 · Phase 2 |
 Wuhan YZY Biopharma Co., Ltd.2496 · HKEX | 2 assets: 1 Ph 3, 1 Ph 1 | M701Phase 3 · Non-Small Cell Lung Cancer | None on record |
 3D Medicines Inc.1244 · HKEX | 1 asset: 1 Ph 1 | 3D189Phase 1 · Multiple Myeloma | None on record |
 Alebund Pharmaceuticals9637 · HKEX | 1 asset: 1 Ph 3 | AP301 (fiber-iron phosphate binder)Phase 3 · Chronic Kidney DiseasePartial signal | None on record |
 Antengene Corporation Limited6996 · HKEX | 1 asset: 1 approved | Approved assets only | Dec 2026Selinexor · Phase 2/3 |
 Beijing Biostar Pharmaceuticals2563 · HKEX | 1 asset: 1 Ph 3 | UtidelonePhase 3 · Non-Small Cell Lung CancerPartial signal | 1 Dec 2026Utidelone · Phase 2 |
 CStone Pharmaceuticals2616 · HKEX | 1 asset: 1 Ph 3 | CS1001 Monoclonal AntibodyPhase 3 · Non-Small Cell Lung CancerReliable signal | None on record |
 Consun Pharmaceutical Group1681 · HKEX | 1 asset: 1 Ph 1 | SK-08Phase 1 · Chronic Kidney Disease | None on record |
 Everest Medicines (Beijing) Co., Ltd.1952 · HKEX | 1 asset: 1 Ph 2 | EVM14Phase 1/2 · Non-Small Cell Lung Cancer | Jul 2028EVM14 · Phase 1 |
 Insilico Medicine3696 · HKEX | 1 asset: 1 Ph 2 | garutadustatPhase 2 · Ulcerative Colitis | 15 Aug 2027garutadustat · Phase 2 |
 Lee's Pharmaceutical0950 · HKEX | 1 asset: 1 approved | Approved assets only | None on record |
 Shaanxi Micot Pharmaceutical Technology2335 · HKEX | 1 asset: 1 Ph 3 | MT1013Phase 3 · Chronic Kidney DiseasePartial signal | 26 Nov 2026MT1013 · Phase 3 |
 Shandong Boan Biotechnology Co., Ltd6955 · HKEX | 1 asset: 1 Ph 1 | BA1302Phase 1 · Non-Small Cell Lung Cancer | None on record |
 Shanghai Bao Pharmaceuticals Co., Ltd.2659 · HKEX | 1 asset: 1 Ph 1 | KJ015Phase 1 · Non-Small Cell Lung Cancer | 31 Dec 2026KJ015 · Phase 1 |
 Sihuan Pharmaceutical Holdings0460 · HKEX | 1 asset: 1 Ph 3 | janagliflozinPhase 3 · Type 2 DiabetesReliable signal | None on record |
 SinoMab BioScience3681 · HKEX | 1 asset: 1 Ph 2 | SM17Phase 2 · Atopic DermatitisPartial signal | 25 Apr 2027SM17 · Phase 2 |
 TYK Medicines, Inc.2410 · HKEX | 1 asset: 1 Ph 3 | TY-9591Phase 3 · Non-Small Cell Lung CancerWeak signal | 1 Dec 2027TY-9591 · Phase 2 |
 TransThera Sciences (Nanjing), Inc.2617 · HKEX | 1 asset: 1 Ph 3 | TinengotinibPhase 3 · HR+/HER2- Metastatic Breast Cancer | Dec 2026Tinengotinib · Phase 3 |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).